Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …

Importance Metastatic non–small cell lung cancer (mNSCLC) withEGFRexon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10%
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

Purpose: To assess the utility of the cobas EGFR Mutation Test, with tissue and plasma, for
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …